Drug Substance (DS) aims to accelerate the way our operations deliver near- term results.
The DS Phorum enables biomanufacturers to collaborate on their most challenging operational strategies.
Formed in 2018, Cell & Gene Therapy (CGT) supports the quest for better and faster development of cell and gene therapies.
BioPhorum IT’s (BPIT) mission is to accelerate the delivery of information technology-impacted business goals and to help unlock the value of the pharmaceutical industry’s IT opportunities.
SP brings together biomanufacturers with supply partners to create a genuine supply chain partnership that is unique in the biomanufacturing industry.
Technology Roadmapping (TR) is a collaborative technology management process that accelerates innovation and development of the manufacturing processes of the future.
In BioPhorum Fill Finish (FF) you will find representatives of the world’s top sterile filling operations developing solutions to some of the most intractable technical and regulatory challenges.
BioPhorum Development Group’s mission focuses on better and faster process development of biopharmaceutical medicines. Formed in 2011, the Phorum has succeeded in bringing collaboration to the drug development community while navigating the challenges of being close to intellectual property.
BioPhorum MedTech is a new Phorum which will address the unique challenges faced in combination product development and manufacture.
With a clear focus on regulatory compliance, drug-device co-development, device design, digital healthcare and supply chain, BioPhorum MedTech provides a platform for companies to share real-world challenges and experiences in a safe, open and collaborative setting.
The biopharmaceutical industry continues to develop advanced best practice manufacturing processes, systems, technologies and facilities. However, we experience varying degrees of understanding and confidence across manufacturers and regulators.
To act as a voice of the industry to enable delivery of the industry’s sustainability ambition quickly and effectively.
To lead innovative teams who have the capability and credibility to create consensus and ultimately drive real change that benefits people and planet.
by Emma Howlett | Oct 4, 2021The aim of ICH Q12 is clearly stated as a framework to facilitate the management of post-approval CMC changes. The biopharmaceutical industry through these comments commends the agency on leading the way to the implementation of ICH Q12. The BioPhorum comments are...